June 24, 2017
Welcome Address	D. Robert Siemens	VIEW
Canadian Urologic Oncology Group Lecture - Telling tales of precision oncology in CRPC	Martin E. Gleave	VIEW
State-of-the-Art Lecture 1 - Optimizing active surveillance for prostate cancer	Stacy Loeb	VIEW
Educational Forum 1
Enhancing prostate cancer screening and care in 2017 using radiological and molecular advances made in the last decade
Session introduction by David Penson followed by Nutrition, Exercise and weight loss in Prostate Carcinoma by J. Brantley Thrasher	David Penson /  J. Brantley Thrasher	VIEW
Prostate Cancer Screening: "Official" Canadian Perspective	Neil E. Fleshner	VIEW
The Utility of Serum and Urine Markers to Select Patients for Initial and Repeat Biopsy	Stacy Loeb	VIEW
The Role of mpMRI in Active Surveillance	Franck Bladou	VIEW
The Role of Multiparametric MRI in Prostate Cancer Screening	Franck Bladou	VIEW
The Future of PSA Screening	Laurence H. Klotz	VIEW
June 25, 2017
State-of-the-Art Lecture 2 - Immunotherapy for urologic cancers	Kim Chi	VIEW
Educational Forum 2
Optimizing quality of care in bladder cancer	Peter Chung	VIEW
	Girish S. Kulkarni	VIEW
	Bobby Shayegan	VIEW
	Adrian Fairey	VIEW
State-of-the-Art Lecture 3 - What's important in infertility 2017	Peter Schlegel	VIEW
Podium Session 1: Early Prostate Cancer
Magnetic resonance imaging-targeted vs. systematic biopsies in men on active surveillance: Results of a prospective, randomized Canadian Urology Research Consortium trial	Laurence H. Klotz	VIEW
Germline mutations in the kallikrein 6 region and predisposition for aggressive prostate cancer	Alexandre Zlotta	VIEW
Association between germline genetic variation and progression in men with low-risk prostate cancer on active surveillance	Viranda Jayalath	VIEW
Defining a cohort of men who may not require repeat prostate biopsy based on the negative predictive value of PCA3 and magnetic resonance imaging combined: The double-negative effect	Nathan Perlis	VIEW
Prostate-specific antigen levels in men aged 60?70 and development of lethal prostate cancer over 30 years: Implications for risk-stratified screening	Mark A. Preston	VIEW
Outcomes of an aggressive biopsy strategy in young men with prostate-specific antigen between 0.5 and 2.5	Hanan Goldberg	VIEW
CUA Historian	Jerzy B. Gajewski	VIEW
CUA Scholarship Foundation Lecture - The essential role of urology in transplantation: For service for innovation	Patrick P. Luke	VIEW
Allied Urological Association Address
Allied Urological Association Address	Brant Thrasher	VIEW
	Christopher Chapple	VIEW
	Mark Speakman	VIEW
Educational Forum 3
First do no harm: Avoiding urological overtreatment	Luc Valiquette	VIEW
	Trustin S. Domes	VIEW
	Timothy Averch	VIEW
	Patrick Richard	VIEW
State-of-the-Art Lecture 4 - Twins separated at birth: Vesicoureteral reflux and prostate cancer	Barry Kogan	VIEW
Educational Forum 4
Building the bridge of transition	Melise Keays	VIEW
	Barry Kogan	VIEW
	Blayne K. Welk	VIEW
June 26, 2017
State-of-the-Art Lecture 5 - The contemporary use of mesh in prolapse and incontinence surgery	J. Christian Winters	VIEW
Educational Forum 5- Still leaking, now what? Refractory OAB, recurrent SUI and mesh concerns	J. Christian Winters	VIEW
Podium Session 2: General Urology
Incidence, treatment and risk of adverse birth outcomes for kidney stones in pregnancy: A population-based study	Michael Ordon	VIEW
Evaluating the efficacy and safety of intravesical onabotulinumtoxinA in older patients with idiopathic overactive bladder	Adiel E. Mamut	VIEW
Low risk of clean intermittent catheterization and improved treatment response in a post-hoc analysis of a diverse age group of onabotulinumtoxinA-treated patients with overactive bladder	Sidney B. Radomski	VIEW
Randomized, controlled trial comparing narrow vs. wide focal zones for shock wave lithotripsy of renal calculi	Monica A. Farcas	VIEW
Understanding simple cystectomy for benign disease: A unique patient cohort with significant risks	Henry Tran	VIEW
Educational Forum 6
BPH emerging technologies / techniques: Way of the future or passing trend?	Mark Speakman	VIEW
	Christopher Chapple	VIEW
	Sidney B. Radomski	VIEW
	Naeem Bhojani	VIEW
State-of-the-Art Lecture 7 - CAUS Lecture - Chasing zero: The safety imperative for Canadian health care	Peter Pisters	VIEW
June 27, 2017
State-of-the-Art Lecture 8 - Improving the quality of medical management of stone disease	Timothy Averch	VIEW
Educational Forum 7 - Optimizing stone surgery outcomes	Timothy Averch	VIEW
State-of-the-Art Lecture 9 - What’s new in patient-reported outcomes following treatment for localized prostate cancer?	David Penson	VIEW
Educational Forum 8
Challenging issues in post-prostate cancer care	Sender Herschorn	VIEW
	Gregory Bailly	VIEW
Challenging issues in post-prostate cancer care	Brant Thrasher	VIEW
Podium Session 4: Other Oncology
Four vs. 10 months of induction androgen-deprivation therapy for intermittent therapy (the FIT trial): A prospective Canadian Urology Research Consortium randomized trial	Laurence H. Klotz	VIEW
Safety of minimizing intensity of followup on active surveillance for clinical stage I testicular germ cell tumours	Matthew Da Silva	VIEW
Long-term followup of small renal masses: A prospective cohort study	Emily Whelan	VIEW
Dense dose combination of methotrexate/vinblastine/doxorubicin/cisplatin vs. gemcitabine/cisplatin in patients with cT3-4a bladder cancer treated with radical cystectomy: A real-world experience	Wassim (Wes) Kassouf	VIEW
A propensity score analysis of radical cystectomy vs. bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic	Girish S. Kulkarni	VIEW
Phase 2 randomized trial of rectus sheath vs. epidural blockade for postoperative analgesia in bladder cancer patients undergoing open radical cystectomy: Results of a data monitoring committee-mandated interim analysis	Alexandra Bascom	VIEW
CUA Guidelines
Adult Overactive Active Bladder (OAB) Guideline	Lysanne Campeau	VIEW
Management of Muscle Invasive Bladder Cancer (MIBC) Guideline	Girish S. Kulkarni	VIEW
Canadian Urological Association recommendations on prostate cancer screening and early diagnosis	Ross Mason	VIEW